These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Audit of anticoagulant therapy of pulmonary embolus, deep vein thrombosis and thrombophlebitis. Meinhold JM; Reale EO; Miller WA Am J Hosp Pharm; 1979 Feb; 36(2):214-8. PubMed ID: 420210 [TBL] [Abstract][Full Text] [Related]
5. Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. Bjornsson TD; Schneider DE; Hecht AR J Pharmacol Exp Ther; 1988 Jun; 245(3):804-8. PubMed ID: 3164387 [TBL] [Abstract][Full Text] [Related]
6. Locally available heparin modulates inflammatory cell recruitment in a manner independent of anticoagulant activity. Lever R; Smailbegovic A; Page CP Eur J Pharmacol; 2010 Mar; 630(1-3):137-44. PubMed ID: 20043903 [TBL] [Abstract][Full Text] [Related]
7. Role of heparin in reducing skeletal muscle infarction in ischemia-reperfusion. Hobson RW; Neville R; Watanabe B; Canady J; Wright JG; Belkin M Microcirc Endothelium Lymphatics; 1989; 5(3-5):259-76. PubMed ID: 2637945 [TBL] [Abstract][Full Text] [Related]
8. Heparin decreases permeability of pig urinary bladder wall preliminarily enhanced by chitosan. Kos MK; Bogataj M; Mrhar A Drug Dev Ind Pharm; 2008 Feb; 34(2):215-20. PubMed ID: 18302041 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass. Terrell MR; Walenga JM; Koza MJ; Pifarré R Ann Thorac Surg; 1996 Aug; 62(2):506-11. PubMed ID: 8694614 [TBL] [Abstract][Full Text] [Related]
10. Characterization of a new potent heparin. 1 communication: Determinations of anticoagulant activity of a high potency heparin preparation in vivo using dog as an experimental animal and in vitro using dog and human plasma. Bhargava AS; Heinick J; Schöbel C; Günzel P Arzneimittelforschung; 1980; 30(6):993-6. PubMed ID: 7191280 [TBL] [Abstract][Full Text] [Related]
11. A new plastic collection tube made of polyethylene terephtalate is suitable for monitoring traditional anticoagulant therapy (oral anticoagulant, unfractionated heparin, and low molecular weight heparin). Toulon P; Ajzenberg N; Smahi M; Guillin MC Thromb Res; 2007; 119(2):135-43. PubMed ID: 16426667 [TBL] [Abstract][Full Text] [Related]
13. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ Blood Coagul Fibrinolysis; 2007 Sep; 18(6):547-53. PubMed ID: 17762530 [TBL] [Abstract][Full Text] [Related]
14. [The influence of the Soviet antimalarial preparation dabequin on the hemostatic system and on the anticoagulant effect of heparin]. Pomortseva IV; Ovchinnikova LK; Shcheglova NV Farmakol Toksikol; 1990; 53(1):59-62. PubMed ID: 2328805 [TBL] [Abstract][Full Text] [Related]
15. Topical heparin: new observations. Cesarone MR; Belcaro G; Errichi S; Cornelli U; Pellegrini L; Ruffini I; Errichi BM; Ledda A; Vinciguerra G; Ricci A; Gizzi G; Ippolito E; Fano F; Dugall M; Cacchio M; Di Renzo A; Hosoi M; Grossi MG; Stuard S; Corsi M Angiology; 2007; 58 Suppl 1():16S-20S. PubMed ID: 17478878 [TBL] [Abstract][Full Text] [Related]
16. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis. Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415 [TBL] [Abstract][Full Text] [Related]
17. In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant. Shammas NW; Lemke JH; Dippel EJ; McKinney DE; Takes VS; Youngblut M; Harris M; Harb C; Kapalis MJ; Holden J J Invasive Cardiol; 2003 May; 15(5):242-6. PubMed ID: 12730630 [TBL] [Abstract][Full Text] [Related]
18. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects. Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715 [TBL] [Abstract][Full Text] [Related]
20. Bleeding times in rats treated with heparin, heparin fragments of high and low anticoagulant activity and chemically modified heparin fragments of low anticoagulant activity. Palm M; Mattsson C; Svahn CM; Weber M Thromb Haemost; 1990 Aug; 64(1):127-32. PubMed ID: 2177229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]